SCHEMBL23775748

SCHEMBL23775748

CC(C)c1cccc(C(=O)I)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.50
▸ RXRB P28702 1/20 0.50
▸ RXRG P48443 1/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ MAPT P10636 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HDAC4 P56524 2/20 0.48
▸ HDAC8 Q9BY41 2/20 0.48
▸ MDM4 O15151 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ TYR P14679 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ CA5A P35218 1/20 0.48
▸ HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11756980 0.83 MAPT (0.65) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL3887369 0.82 RXRA (0.51) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL30444032 0.82 RXRA (0.66) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL105264 0.82 RXRA (0.66) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL2737366 0.82 RXRA (0.51) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL4052625 0.80 RXRA (0.50) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL2623891 0.80 KDM4E (0.50) RXRARXRBRXRGSMN1; SMN2MAPT
Ethane SCHEMBL5407515 0.80 RXRA (0.50) RXRARXRBRXRGSMN1; SMN2MAPT
SCHEMBL84456 0.80 PARP1 (0.57) RXRARXRBRXRGSMN1; SMN2MAPT
Hydrogen Peroxide SCHEMBL9061056 0.80 RXRA (0.54) RXRARXRBRXRGSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORPORATION 2024-02-29 — — US disclosed
US-11781168-B2 Process for preparing substituted imidazo[1,2-α]pyrazines PROMEGA CORPORATION (US) 2023-10-10 — — US disclosed
US-20210254128-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2021-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11781168-B2 Process for preparing substituted imidazo[1,2-α]pyrazines CYP4Z1, CYP2E1, CYP2F1 RXRA 3320/4885RXRB 3520/4885RXRG 3835/4885
US-20210254128-A1 COELENTERAZINE ANALOGUES AADAC, GLB1, PGLS RXRA 4188/4885RXRB 3920/4885RXRG 3943/4885
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PGLS, AADAC, GLB1 RXRA 3965/4885RXRB 3968/4885RXRG 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback